Paolo Ghia - Concepedia

Author

Paolo Ghia

Vita-Salute San Raffaele University ORCID

Also Known As

Ghia, Paolo, Michael Hallek, P GHIA, P Ghia, P. Ghia, PAOLO GHIA, Paolo Ghia, Paolo Prospero Ghia

1.1K

Publications

36.6K

Citations

H-Index

142

Concepts

All Affiliations

Vita-Salute San Raffaele University IRCCS Ospedale San Raffaele Istituti di Ricovero e Cura a Carattere Scientifico The University of Texas MD Anderson Cancer Center St James's University Hospital

About

Paolo Ghia is an author at Vita-Salute San Raffaele University specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	92	8.5K
2	Health Sciences	23	31	4.3K
3	Engineering	2	2	96
4	Natural Sciences	2	2	65
5	Nursing	1	1	14

Paolo Ghia

293

Publications

28.5K

Citations

H-Index

Page 1

	Year	Citations
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, New England Journal of Medicine	2015	1.5K
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Elı́as Campo, Elaine S. Jaffe, James R. Cook, Blood ImmunologyPathologyInternational Consensus ClassificationDermatologyLymphoid Neoplasms	2022	1.4K
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Bonnie K. Harrington, Susan O’Brien, New England Journal of Medicine	2015	878
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Blood	2015	693
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial John C. Byrd, Peter Hillmen, Paolo Ghia, Journal of Clinical Oncology	2021	594
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Barbara Eichhorst, Tadeusz Robak, Emili Montserrat, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineMixed-phenotype Acute Leukemia	2015	590
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology	2020	583
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Barbara Eichhorst, Tadeusz Robak, Emili Montserrat, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineMixed-phenotype Acute Leukemia	2020	548
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations Chrysoula Belessi, Carol Moreno, Myriam Boudjograh, Blood	2006	528

Page 1